Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Cerilliant
Deloitte
Baxter
Cipla
Accenture
Moodys
Queensland Health
Mallinckrodt

Generated: April 20, 2018

DrugPatentWatch Database Preview

Tentative Approvals for: Hetero Labs Ltd V

« Back to Dashboard

Hetero Labs Ltd V Drugs with Tentative Approvals

Applicant Generic Name NDA Strength Dosage Form
Hetero Labs Ltd V abacavir sulfate;lamivudine 205412 600;300MG TABLET;ORAL
Hetero Labs Ltd V sildenafil citrate 202659 EQ 25MG BASE TABLET; ORAL
Hetero Labs Ltd V sildenafil citrate 202659 EQ 100MG BASE TABLET; ORAL
Hetero Labs Ltd V eltrombopag 206788 75MG TABLET;ORAL
Applicant Generic Name NDA Strength Dosage Form

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Citi
McKinsey
Healthtrust
QuintilesIMS
Cantor Fitzgerald
Moodys
Farmers Insurance
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.